In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …

Several studies have revealed that the hyper-inflammatory response induced by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease …

B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case …

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Background The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over
100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during …

Chimeric antigen receptor (CAR) T‐cell therapy is a promising immunotherapeutic treatment
concept that is changing the treatment approach to hematologic malignancies. The …

Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells
(CAR-T cells) have great potential to treat many human diseases; however, inflammatory …